Probiotics: a promising future in the treatment of ulcerative colitis?
- PMID: 40214948
- DOI: 10.1007/s43440-025-00724-7
Probiotics: a promising future in the treatment of ulcerative colitis?
Abstract
Ulcerative colitis is an idiopathic and chronic inflammatory bowel disease, characterized by inflammation of the mucosa of the colon and rectum. Clinical manifestations commonly include abdominal pain, diarrhea (with or without hematochezia), and weight loss. The pathogenesis of ulcerative colitis is multifactorial, involving a combination of genetic predispositions and lifestyle factors. High consumption of processed food, sedentary habits, alcohol intake, and stress are among the lifestyle factors implicated in disease onset and progression. Current treatment strategies focus on managing symptoms and inducing remission, however, the chronic nature of the disease, along with the adverse effects of conventional therapies, often compromises patient's quality of life. Therefore, exploring alternative therapies that can prolong remission and reduce symptom burden is important. Experimental evidence suggests that probiotics may extend remission duration in ulcerative colitis. Moreover, probiotics exhibit efficacy in amelioration clinical symptoms by reducing inflammation markers, preserving, and restoring intestinal epithelial. This review explores the advantages of the administration of probiotics in the treatment of ulcerative colitis, elucidating their mechanism of action.
Keywords: Gut health; Gut microbiome; Inflammation; Inflammatory bowel disease; Oxidative stress.
© 2025. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.
Conflict of interest statement
Declarations. Ethics and consent to participate declarations: Not applicable, as this study is a review article and does not involve the collection of data from human or animal subjects. Competing interests: The authors declare no competing interests.
References
-
- Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;29(10080):1756–70. https://doi.org/10.1016/S0140-6736(16)32126-2 . - DOI
-
- Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, et al. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65(12):100851. https://doi.org/10.1016/j.disamonth.2019.02.004 . - DOI - PubMed
-
- Aslam N, Lo SW, Sikafi R, Barnes T, Segal J, Smith PJ, et al. A review of the therapeutic management of ulcerative colitis. Th Adv Gastroenterol. 2022;29:15:17562848221138160. https://doi.org/10.1177/17562848221138160 . - DOI
-
- Latif A, Shehzad A, Niazi S, Zahid A, Ashraf W, Iqbal MW, et al. Probiotics: mechanism of action, health benefits and their application in food industries. Front Microbiol. 2023;17:14:1216674. https://doi.org/10.3389/fmicb.2023.1216674 . - DOI
-
- Palumbo VD, Romeo M, Marino Gammazza A, Carini F, Damiani P, Damiano G, et al. The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160(3):372–7. https://doi.org/10.5507/bp.2016.044 . - DOI - PubMed
Publication types
MeSH terms
Grants and funding
- 305740/2019-9/Conselho Nacional de Desenvolvimento Científico e Tecnológico
- 309431/2022-0/Conselho Nacional de Desenvolvimento Científico e Tecnológico
- 308220/2021-8/Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Edital 15/2022 - PROFIX: 708/2022/Fundação de Amparo à Pesquisa e Inovação do Espírito Santo
- Edital 15/2022 - PROFIX: 630/2022/Fundação de Amparo à Pesquisa e Inovação do Espírito Santo
LinkOut - more resources
Medical